EV Biologics was previously a NASDAQ-listed company and intends to up-list to a mainboard exchange again before the end of 2021. Please visit our website: www.evbiologics.com/about Exosomes
The director’s loan will be repaid in cash after the intended security token sale later this summer. No shares will be issued pursuant to any future funding. CEO Daniel Mckinney, said “we have set an aggressive timeline to produce our own optimized cell line and exosomes, and with this funding we will achieve it. Our ultimate audacious goal is to conquer incurable diseases and to revolutionize modern medicine.”
EV Biologics is building a world-class team of exosome biotechnology experts specializing in molecular biology, biochemical engineering, biomanufacturing, cellular biochemistry, bioinformatics and computational biology. This internal funding will finance immediate generation of this master cell bank, which will serve as a versatile platform for production of exosomes with a broad scope of potential clinical applications. These funds will also enable immediate production of research-grade exosomes from induced pluripotential stem cells (iPSCs) and their derivatives for evaluation of native exosome bioactivity and further bioengineering. This research will inform and expedite our ongoing effort to engineer exosomes optimized for specific clinical applications.
EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, intent on bringing human mesenchymal “MSC” and other stem cell and cell-derived products to market in the cosmetic and biopharmaceutical spaces. Initially, these novel and unique products will be specifically provided to the international clinical research community including universities and physicians and will be targeted to the aesthetic and regenerative medicine markets. Using proprietary and patentable technologies, the Company is creating exclusive IP and IT inherent in our superior products. Further product development will be focused on investigation of novel stem cell-derived biopharmaceuticals designed for specific clinical conditions. Forward-Looking Statements About the Company
The intrinsic properties of exosomes in regulating complex intracellular pathways has advanced their potential utility in the therapeutic control of many diseases, including neurodegenerative conditions and cancer. Exosomes can be engineered to deliver diverse therapeutic payloads, including short interfering RNAs, antisense oligonucleotides, chemotherapeutic agents, and immune modulators, with an ability to direct their delivery to a desired target. – Science, 2020 Exosomes are nano-sized vesicles that serve as mediators for cell-to-cell communication. With their unique nucleic acids, proteins, and lipids cargo compositions that reflect the characteristics of producer cells, exosomes can be utilized as cell-free therapeutics. – Cells, 2020
The News Highlights
- EV Biologics confirms funding to start cell line generation and advanced exosome research
- Check the latest Gaming news updates and information about games.
- Please share this news with your friends and family to support us your one share helps us a lot.
- Follow us on Facebook and Twitter, for similar updates.
For Latest News Follow us on Google News
- Show all
- Trending News
- Popular By week